(19)
(11)EP 3 623 385 A8

(12)CORRECTED EUROPEAN PATENT APPLICATION
Note: Bibliography reflects the latest situation

(15)Correction information:
Corrected version no 1 (W1 A1)

(48)Corrigendum issued on:
06.05.2020 Bulletin 2020/19

(43)Date of publication:
18.03.2020 Bulletin 2020/12

(21)Application number: 19192268.1

(22)Date of filing:  15.11.2012
(51)Int. Cl.: 
C07K 16/28  (2006.01)
A61P 35/02  (2006.01)
A61K 39/395  (2006.01)
A61P 37/00  (2006.01)
(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30)Priority: 15.11.2011 US 201161560144 P
15.11.2011 US 201161560149 P
15.11.2011 US 201161560162 P
15.11.2011 US 201161560178 P
15.11.2011 US 201161560183 P
24.05.2012 US 201261651474 P
24.05.2012 US 201261651486 P

(62)Application number of the earlier application in accordance with Art. 76 EPC:
12803509.4 / 2780374

(71)Applicants:
  • Amgen Research (Munich) GmbH
    81477 München (DE)
  • Amgen Inc.
    Thousand Oaks, California 91320-1799 (US)

(72)Inventors:
  • KUFER, Peter
    81477 Munich (DE)
  • RAUM, Tobias
    81477 Munich (DE)
  • HOFFMANN, Patrick
    81477 Munich (DE)
  • KISCHEL, Roman
    81477 Munich (DE)
  • LUTTERBUESE, Ralf
    81477 Munich (DE)
  • RAU, Doris
    81477 Munich (DE)
  • ADAM, Paul
    55216 Ingelheim am Rhein (DE)
  • BORGES, Eric
    55216 55216 Ingelheim am Rhein (DE)
  • HEBEIS, Barbara
    55216 Ingelheim am Rhein (DE)
  • HIPP, Susanne
    55216 Ingelheim am Rhein (DE)

(74)Representative: Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB 
Ganghoferstraße 68 B
80339 München
80339 München (DE)

 
Remarks:
This application was filed on 19-08-2019 as a divisional application to the application mentioned under INID code 62.
 


(54)BINDING MOLECULES FOR BCMA AND CD3


(57) The present invention relates to a binding molecule comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope clusters of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.